AAM’s Baeder Takes A Focused Approach To Articulating Industry Priorities
New Association Chair Says US Is At An ‘Inflection Point’ For Generics Sustainability
Executive Summary
Christine Baeder, Teva’s chief operating officer for US generics and biosimilars, was named chair of the AAM’s board in February. Speaking with Generics Bulletin, she sets out her priorities against the backdrop of a US generics industry that is now at an “inflection point” for sustainability.
You may also be interested in...
AAM Warns Over Biden Budget Plans To Extend IRA
US generics and biosimilars association the AAM has offered a frosty response to budget plans announced by the Biden administration that include expanding the scope of price negotiation under the Inflation Reduction Act.
‘Disruptor’ Mark Cuban Takes Aim At US Industry Barriers
During a lively discussion at the AAM’s Access! conference in Orlando, billionaire entrepreneur Mark Cuban set out how he plans to use his Cost Plus Drugs company to disrupt the generics sector while also lifting its reputation by increasing trust and transparency among patients.
Leonard Resignation Leaves AAM Looking For New Leadership
Dan Leonard has announced his resignation as president and CEO of the US Association for Accessible Medicines. He will be replaced on an interim basis by the group’s vice president for sciences and regulatory affairs, David Gaugh.